AI Insight
This randomized, double-blind, placebo-controlled trial of 93 overweight adults found that CLB101TM, a probiotic containing the butyrate-producing bacterium Anaerostipes caccae, significantly reduced gastrointestinal symptom burden after 28 days of supplementation. The treatment group showed statistically significant improvements in overall GI symptoms, reflux, and abdominal pain compared to placebo, with only three self-limiting adverse events reported. The probiotic was well-tolerated with 97.7% adherence, though the study population did not show baseline signs of intestinal barrier dysfunction.
Why it matters
This study provides clinical evidence that a next-generation butyrate-producing probiotic may offer a safe treatment option for managing common gastrointestinal symptoms in overweight adults, potentially addressing digestive discomfort without significant side effects. If validated through peer review, this could expand therapeutic options for functional GI complaints.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background. Anaerostipes caccae CLB101TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods. Ninety-three adults were randomized 1:1 to CLB101TM ( n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results. 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101TM administration. CLB101TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: -1.60 vs -0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: -1.26 vs -0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: -1.86 vs -0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions. CLB101TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration. The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov (NCT07336615).